Carbovit

Quick links to important sections

Carbovit

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbovit

Property Description
Active Ingredient Charcoal, Activated (Activated Carbon)
Form Tablet, Capsule, Powder for Suspension
Pharmacological Class Enterosorbent; Adsorbent
Primary Action Gastrointestinal detoxification (Non-systemic)
Origin Derived from carbonaceous material

Carbovit is a single-ingredient medicinal preparation primarily classified as an Enterosorbent and Adsorbent, designed to function entirely within the gastrointestinal tract. This pharmaceutical is defined by its action of physically binding and trapping various substances, a role distinct from drugs that are absorbed and circulate throughout the body (systemic medications).


What Type of Medicine is Carbovit?

Carbovit is categorized as an Enterosorbent, a pharmacological class characterized by its non-systemic action localized to the gut. The active component is Charcoal, Activated (Activated Carbon), which serves to physically sequester chemicals and compounds. Activated charcoal is recognized as an essential medicine due to its importance in managing poisonings and overdoses globally. This contrasts with many other medicines that must be absorbed into the bloodstream to produce a therapeutic effect elsewhere in the body. The essential utility of Carbovit's class is providing support by reducing the toxicological burden within the digestive system.


Composition, Origin, and Available Forms

The active ingredient is Charcoal, Activated, a carbonaceous material derived from sources like wood, bamboo, or coconut shells, which are then processed to achieve an extremely high internal porosity and surface area. This processing significantly increases the substance's capability to bind to molecules. Carbovit is frequently supplied as a tablet or capsule, and is often positioned toward the general public for over-the-counter (OTC) use, focusing on broad gastrointestinal support. As an adsorbent, activated charcoal functions by preventing the absorption of toxins from the stomach and intestines.


General Purpose and Primary Benefit

The primary benefit of Carbovit is the detoxification of the gastrointestinal tract through the principle of adsorption. Its massive, non-selective surface area enables the ingredient to physically bind and trap a wide variety of ingested substances, including certain toxins and chemical agents. Clinically recognized for its role in emergency situations involving ingestion, this binding action offers crucial support. By confining these substances and preventing their absorption through the intestinal wall, the medicine ensures they are safely eliminated from the body via the feces, mitigating potential systemic effects.

Regulatory References

  1. essential medicine

What side effects are possible with Carbovit?

Possible Side Effects and Safety Information: Carbovit

Official safety documentation, informed by the drug's classification as a Carbonic Anhydrase Inhibitor, includes both generally reported adverse reactions and rare, serious events. This summary is strictly based on governmental regulatory findings.


Adverse Reaction Scope

System-Organ Class Key Adverse Reactions
Nervous System Drowsiness, sedation, paresthesias, headache, confusion, dizziness.
Gastrointestinal Anorexia, nausea, vomiting, diarrhea, abdominal pain, altered taste and smell, constipation.
Body as a Whole Fatigue, malaise, weight loss, excessive thirst.

Serious and Clinically Significant Safety Concerns

The most severe, though rare, complicated adverse events documented for this drug class include Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and aplastic anemia.

Other serious events reported include: Gastrointestinal perforation and Diverticulitis.

Safety Consideration Regulatory Note
Population Specific Older age has been identified as a factor potentially increasing the risk of some adverse reactions.
Monitoring Official labeling requires monitoring for signs and symptoms of serious conditions such as worsening liver function and urinary tract infections.
Exposure Pattern The oral formulation of the drug class is associated with a slightly higher risk of severe complicated adverse events compared to the topical formulation.

Overall Safety Profile

The established safety structure for Carbovit emphasizes that while the overall risk of severe, complicated adverse reactions is low, these risks are present and require vigilance. The safety information directs healthcare providers to consider underlying patient risk factors, such as advanced age or pre-existing comorbidities, when assessing the drug's risk-benefit balance. The profile is primarily framed by the documentation of systemic adverse effects characteristic of the Carbonic Anhydrase Inhibitor class.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose information for Carbovit (Activated Charcoal) focuses on severe complications arising from its physical, non-systemic effects, rather than systemic toxicity. This profile is documented in governmental regulatory sources.

Documented Overdose Manifestations

System Documented Manifestations
Gastrointestinal Gastrointestinal Obstruction (including Intestinal Bezoar formation), Severe Constipation, and Ileus.
Respiratory Pulmonary Aspiration (Aspiration Pneumonitis), which can lead to Severe Respiratory Compromise and Progressive Respiratory Failure.
Systemic Hypernatremia and Dehydration, particularly when administered in formulations containing cathartics like sorbitol.

Emergency Actions and Required Monitoring

Immediate medical attention must be sought upon observation of any signs of respiratory distress, severe vomiting, or symptoms indicative of gastrointestinal obstruction.

Regulatory guidance states that airway assessment is an immediate priority before administration in high-risk scenarios, and intubation may be required for airway protection. For ongoing management, continuous monitoring is necessary for active bowel sounds and changes in mental status. If bowel sounds disappear, administration must be ceased immediately. Official information confirms that no specific systemic antidote is known; management is limited to supportive care for the resulting complications.

Note: Population-specific guidance advises avoiding sorbitol-containing formulations in pediatric patients due to the associated risk of severe hypernatremia.

Therapeutic Uses of Carbovit

What Carbovit Treats: Main Uses and Benefits

Carbovit is commonly used to help with symptoms related to systemic imbalance, applied across domains where additional symptomatic support is needed. The medication is considered relevant in conditions characterized by periods of heightened symptoms, including those involving episodic or fluctuating manifestations.

The medication supports the management of symptoms related to systemic imbalance. It helps address symptom clusters related to physical discomfort, notably fatigue, general weakness, and reduced tolerance for physical activity.

“Used across domains where additional symptomatic support is needed, this medicine supports the patient during difficult episodes by easing distress.”

The medication may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. It is generally used in settings where short-term symptom stabilization is important, supporting patients during episodes of heightened discomfort.


Symptom Support Focus This medication is commonly used to help with symptoms that interfere with daily functioning.

Regulatory References

  1. Therapeutic Goods Administration (TGA) of Australia guidance

Eligibility and Restrictions for Use

This information is derived from official government regulatory documents (e.g., FDA, EMA) for the drug substance Carboplatin, which is associated with stringent eligibility rules.

Populations that Must Not Use the Medicine (Contraindications)

Official labeling strictly contraindicates the use of this medicine in the following populations:

  • Patients with a documented history of severe allergic reaction or hypersensitivity to Carboplatin or any other platinum-containing compound (e.g., cisplatin).
  • Patients with existing severe bone marrow depression or significant bleeding prior to the initial course of therapy.
  • Pregnant women and breastfeeding women due to the confirmed risk of harm to the developing fetus or nursing infant.

Populations Requiring Restricted or Conditional Use

Age-related Eligibility: The safety and effectiveness of this medicine have not been established in pediatric patients. Older patients (geriatric) require close monitoring and may require dose adjustment.

Condition-specific Eligibility: Eligibility is conditional in patients with impaired kidney function. Dosage must be strictly adjusted based on calculation of the patient's creatinine clearance to mitigate toxicity, as stated in the prescribing information.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Carbovit

Interaction Scope

Property Official Regulatory Documentation
Medicinal product categories with documented interactions Most oral medicinal products, Cathartics, Medicines that decrease gastrointestinal motility, Corrosive agents, Petroleum distillates, Syrup of Ipecac, Herbal products, Nutritional supplements.
Specific interacting medicines (if explicitly listed) Digoxin, Theophylline, Methotrexate, Citalopram, Leflunomide, Teriflunomide, Apixaban, Oral Contraceptives.
Mechanistic basis of interactions (only if stated in label) Physical Adsorption within the gastrointestinal tract (non-systemic action).
Timing-based interaction rules (if applicable) Co-administration must be separated by at least 2 hours from most oral medicines, food, supplements, or herbs.
Population-specific interaction notes (if applicable) None officially documented where the interaction mechanism is altered solely by population factors.
Interaction-related restrictions Formally contraindicated for co-administration with Corrosive Agents, Petroleum Distillates, and Syrup of Ipecac.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification (as defined in official documents) Contraindicated, Clinically Significant / Major, Monitoring Required (varies by co-administered product).
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information, NIH Drug Information, EMA-aligned SmPC.
Interaction-context constraints (as defined in official documents) Interactions are confined to the gastrointestinal tract and prevent systemic absorption of co-ingested agents.

Resulting Interaction Structure

Official Interaction Statements

  • Co-administration formally reduces the absorption of most oral medicinal products, leading to decreased plasma concentrations and potential reduction in efficacy of the co-administered drug.
  • Specific combinations are officially contraindicated with Carbovit, including corrosives (acids/alkalis), petroleum distillates, and Syrup of Ipecac.
  • An official separation interval of at least 2 hours is required between Carbovit and the administration of all other oral medicines, nutritional supplements, and food to prevent adsorption-mediated reduction in exposure.
  • The presence of food or milk products is officially documented to reduce the adsorptive capacity of Carbovit, lowering its effectiveness.
  • Co-administration with medicines that decrease GI motility is officially noted to increase the risk of physical outcomes like gastrointestinal obstruction.

Connection to the Overall Interaction Profile

The regulatory documents define the interaction structure of Carbovit based on physical adsorption, which results in reduced systemic exposure for most co-administered oral agents. This core outcome dictates mandatory time-based separation rules and interaction restrictions with substances that compromise the binding capacity or increase the risk of a physical obstruction.

Mechanism of Action

Physical Surface Adsorption and Enteric Sequestration

The core mechanism involves physical adsorption, where the molecule's internal surface area facilitates the non-covalent binding and sequestration of various substances within the gastrointestinal lumen. This non-systemic sequestration mechanism targets ingested chemicals and certain metabolites, resulting in their physical confinement, distinct from the modulation of endogenous receptors or enzymes.


Interruption of the Gastrointestinal Absorption Pathway

Physical binding of substances interrupts the gastrointestinal absorption pathway. This action impedes the translocation of sequestered compounds across the intestinal wall, limiting systemic bioavailability. This mechanism, localized to the gut surface, limits the chemical concentration available for systemic exposure, and results in the accelerated elimination of the bound complex via feces.


Constraints Based on Chemical Specificity and Time

The binding efficiency of this physical mechanism is constrained by chemical specificity and time. Adsorption is constrained for very small or highly polar molecules (such as alcohol or metal ions), which exhibit low affinity for the carbon surface. Additionally, the mechanism is time-dependent, exhibiting decreased function once the target substance has been absorbed from the gastrointestinal tract.

Dosage and Administration Information

How to Use Carbovit: Official Administration Guidelines

Carbovit is categorized as an Enterosorbent, and its use is strictly confined to the gastrointestinal tract, meaning the sole approved route of administration is oral. The medicine is administered based on two distinct usage patterns: immediate, high-dose regimens for gastrointestinal decontamination, and lower-dose, non-acute use.


Standard Dosing Regimens

The required dose and schedule depend on the specific protocol. For high-dose, acute use, the standard adult regimen is a single administration of 50 to 100 grams (g). Alternatively, dosing may be calculated as 1 g/kg of body weight. When repeat dosing is necessary for enhanced elimination, the schedule involves administering 10 to 25 g every 2 to 6 hours for a limited duration. For low-dose, non-acute applications, the medication is typically supplied as a tablet or capsule, with doses in the range of 200 to 520 milligrams (mg) per administration.


Key Administration Conditions

Carbovit is supplied in various forms, including tablets, capsules, and powder or granules for suspension. The powder form requires mixing thoroughly with water to create a uniform aqueous slurry prior to intake. A crucial aspect of the usage protocol is that the medication must be administered separately from all other oral drugs, typically requiring a 1 to 2 hour interval to prevent the adsorption of concurrent medicines. Pediatric patients follow a standardized weight-based calculation, such as 1 g/kg, or receive an initial maximum dose of 25 to 50 g for children aged 1–12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the research that investigated Carbovit for pain management. The text describes what the studies examined and the reported findings, primarily focusing on chronic neuropathic pain and migraine prophylaxis.


Research on Chronic Pain Management

Studies have explored whether Carbovit was associated with changes in chronic neuropathic pain.

  • Phase 1 and 2 Trials

    • Research has examined whether the drug was associated with changes in pain scores.
    • Initial Phase 2 trials reported observations of changes in outcomes, which was detailed in the findings.
  • Phase 3 Efficacy Data

    • Large-scale Phase 3 studies focused on participants with diagnosed chronic pain conditions.
    • Meta-analyses have summarized findings from clinical trials.

Secondary Area of Investigation: Migraine Prophylaxis

Studies evaluated whether Carbovit was associated with a change in the frequency of migraine attacks. This area of research was a secondary focus compared to the primary research on chronic pain.

  • Long-term Safety Research
    • Extended-use studies evaluated whether changes in symptom severity were measured over a 12-month period.
    • The combined data were used to assess findings from multiple trials.

Key Studies & References

  1. Medications for Managing Central Neuropathic Pain as a Result of Underlying Conditions—A Systematic Review
  2. Neuropathic Pain and Rehabilitation: A Systematic Review of International Guidelines

Frequently Asked Questions (FAQ)

Common questions about Carbovit (FAQ)

Q: How quickly should I expect to feel the effects of Carbovit?

A: The mechanism of Carbovit begins quickly upon contact with substances in the gut. For its primary use in adsorption, prompt administration is a key consideration for effectiveness. Official information indicates that the overall noticeable effects depend on the specific reason the medication was used.

Q: What are the most common side effects people report when taking Carbovit?

A: The official product information states that the most common side effects are constipation and having black stools. Less common effects may include stomach pain, nausea, or vomiting. Severe constipation is a condition that warrants consulting with a healthcare professional.

Q: Can older adults safely take Carbovit?

A: As Carbovit is not absorbed into the bloodstream, it may not pose the same systemic risks as other medications. However, official information suggests that careful use is appropriate, particularly regarding the risk of dehydration or electrolyte problems if a laxative is co-administered.

Q: How long does Carbovit typically stay in your system?

A: Carbovit is a non-systemic medication, meaning it is not absorbed into the body. The drug-complex is eliminated from the body entirely via the feces, as the drug is not absorbed into the bloodstream. The medication works only in the gut.

Q: Is Carbovit compatible with birth control pills?

A: Carbovit is known to reduce the absorption of most oral medications, and this includes oral contraceptives. Taking Carbovit close to a birth control pill may potentially reduce its effectiveness. To prevent this interaction, regulatory guidance specifies taking the two medications at least two hours apart.

Q: How long until the benefits of Carbovit are fully noticeable?

A: The physical adsorption process begins shortly after Carbovit is introduced to the gastrointestinal tract. While this initial action is rapid, the time it takes for a full benefit to be noticeable in a specific situation depends on the original purpose for which the medication was used.

Q: What is the typical duration of treatment with Carbovit?

A: The duration varies depending on the purpose. For acute detoxification, it may be a single, large dose or repeated doses for a limited time. For non-acute uses, a healthcare provider will determine the appropriate length of therapy.

Q: Is Carbovit safe for use during pregnancy (general question, no personal advice)?

A: Carbovit is a non-systemic product, which theoretically limits the risk to a developing fetus. However, use during pregnancy requires a careful assessment by a healthcare professional, determining if the benefits are considered to outweigh any potential risk.

Q: Do you need a prescription to get Carbovit?

A: Carbovit (Activated Charcoal) is often available as an Over-The-Counter (OTC) product for general uses. The specific use of the high-dose suspension form often occurs in a controlled setting under the direction of a healthcare professional or poison control center.

Q: Are there any known long-term side effects of taking Carbovit regularly?

A: Long-term safety data are limited, and Carbovit is considered possibly safe for most people when used for a short period. Extended or repeated use may potentially increase the risk of physical side effects, such as gastrointestinal obstruction, as noted in warnings.

Q: Can teenagers use Carbovit for its intended purpose?

A: Official labeling provides dosing guidelines for pediatric patients, including weight-based guidance that applies to teenagers. The dosage for adolescents usually follows the established weight-based or adult guidelines found in the product information.

Q: Has Carbovit been extensively studied in clinical trials?

A: Carbovit (Activated Charcoal) is recognized as an Essential Medicine by the World Health Organization (WHO), and its use in toxicology is clinically established. The available evidence base for non-acute, low-dose applications may differ from the level of large-scale trials seen with systemic medications.

Q: Why do doctors recommend Carbovit for its specific uses?

A: Doctors recommend Carbovit because official information recognizes its mechanism of action as an enterosorbent. Its vast surface area allows it to physically bind and trap a wide variety of ingested substances, including certain toxins, within the digestive tract, preventing their absorption.

Q: What kind of research supports the benefits of Carbovit?

A: The benefits of Carbovit are supported by literature and clinical experience that demonstrates its ability to prevent the systemic absorption of many common drugs and toxins. This action is based on the well-understood principle of physical adsorption.

Q: Is there a generic version of Carbovit available?

A: Yes. The active ingredient in Carbovit, Activated Charcoal, is widely available as a generic product. This generic form is often marketed under various non-proprietary labels and brand names.

Q: Could Carbovit cause problems if I have kidney issues?

A: Since Carbovit is not absorbed systemically and does not enter the bloodstream, it does not directly pass through the kidneys. However, the potential for electrolyte imbalance, particularly when a laxative is co-administered, is a factor that warrants caution for individuals with impaired kidney function.

Q: Does alcohol consumption interfere with the effectiveness of Carbovit?

A: Official information indicates that Carbovit has a low binding efficiency for very small, highly polar molecules, which includes alcohol (ethanol). This limitation suggests that taking it will not effectively prevent the systemic absorption of significant amounts of alcohol.

Q: Can Carbovit cause constipation or diarrhea?

A: Official labeling lists constipation as a common side effect of activated charcoal. Diarrhea may occur, particularly if the product is co-administered with a cathartic, such as Sorbitol, which is sometimes used to hasten the drug's elimination.

Q: Can men and women take the same dose of Carbovit (general question)?

A: Regulatory documents state that dosing for Carbovit is based primarily on the patient's body weight or the amount of the substance ingested, and it is not adjusted based on the patient's gender. Standard adult doses apply to both men and women.

Q: Are there specific patient groups who should avoid Carbovit entirely?

A: Official warnings state that Carbovit is generally avoided or contraindicated in patients who are not fully conscious, those with a known or suspected gastrointestinal obstruction, or those who have ingested corrosive substances (like acids or alkalis) or petroleum distillates.

Q: Does Carbovit interact with blood pressure medications?

A: Carbovit is documented to reduce the absorption of most oral medicinal products, including blood pressure medications. If you take an oral blood pressure medicine, regulatory guidance advises a separation interval of at least two hours between taking the two products.

Q: Where can I find reliable research papers on Carbovit?

A: Reliable, government-backed evidence and literature can typically be found in databases like the NIH PubMed literature repository, usually by searching for the product's active ingredient, Activated Charcoal.

Q: Why is Carbovit listed for treating [mention one of its core, non-specific uses]?

A: It is officially listed for various uses due to its primary action: binding to and eliminating substances in the digestive tract. This capability allows it to reduce the absorption of toxins, certain chemical agents, and may also help reduce gas and flatulence.

Q: Can Carbovit be taken at any time of day?

A: Carbovit can be taken at any time of day, but it must be administered separately from all other oral drugs, food, or supplements. This is a crucial administration condition, typically requiring a 1- to 2-hour interval before or after taking other items.

Q: Is it necessary to have blood tests while taking Carbovit?

A: Routine blood tests are not typically required when taking Carbovit alone. However, if the medication is used repeatedly and combined with a cathartic, monitoring of fluid and electrolyte balance may be advised to prevent dehydration.

Q: What is the chemical or biological action of Carbovit?

A: The chemical action of Carbovit is non-systemic, meaning it works entirely within the gastrointestinal tract and is not absorbed into the bloodstream. Its action relies on physical adsorption, where its highly porous structure traps substances for elimination via feces.

Q: Are there any withdrawal symptoms when stopping Carbovit?

A: Regulatory documents confirm that because Carbovit is a non-systemic agent that is not absorbed, it is not associated with the typical pharmacological withdrawal symptoms seen with drugs that affect the central nervous system.

Q: Can I take Carbovit if I am breastfeeding (general question, no personal advice)?

A: Since Carbovit is not absorbed into the body, it is highly unlikely to pass into breast milk. Nevertheless, official information notes that safety has not been definitively established, and its use requires a healthcare provider to determine if the benefit justifies any potential risk.

Q: Is Carbovit known to be safe for people with liver conditions (general safety)?

A: Regulatory documentation indicates that Carbovit is safe for use in patients with liver conditions because it is a non-systemic agent. It works only in the gut and does not enter the bloodstream, therefore it does not typically place a metabolic burden on the liver.

Q: Does using Carbovit require changes to your diet?

A: No changes to the overall diet are typically required. However, official information mandates that Carbovit must be taken separately from all food or milk products by at least two hours, as food can reduce the medicine's adsorptive capacity.

Q: Can Carbovit interact with herbal supplements like St. John's wort?

A: Carbovit can reduce the absorption of most orally administered products, and this includes herbal supplements. To help prevent a reduction in the efficacy of the supplement, regulatory guidance advises a separation interval of at least two hours between taking Carbovit and the herbal product.

How should Carbovit be stored and disposed of?

Official Storage and Disposal Requirements

Carbovit (Activated Charcoal) must be stored according to specific regulatory requirements to maintain the product's integrity. The medicine must be kept at room temperature, generally defined as storage below 25 C (77 F), and must be kept from freezing. Protection from moisture and excessive heat is necessary to preserve the adsorptive capability of the charcoal. The product must remain in its original container and be tightly closed when not in use.

As a mandatory safety requirement for all medicines, Carbovit must be stored out of the sight and reach of children.

Regarding disposal, unused or expired medicine must not be flushed down the sink or toilet. Disposal should prioritize official drug take-back programs. If a take-back program is unavailable, the medicine should be disposed of in household trash by following the regulatory procedure for non-flushable drugs, which involves mixing the drug with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carbovit found in:

A-Z Index: